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LETTER TO THE EDITOR
Angiotensin-Converting Enzyme
Polymorphism (I/D) and
Coronary Heart Disease in Young Adults
The relationship between angiotensin-converting enzyme (ACE)
gene polymorphism and several cardiovascular diseases such as
myocardial infarction (MI) and its prognosis is controversial (1). In
a recent issue of the Journal, Palmer et al. (2) conclude that ACE
genotyping may provide additional prognosis information in pa-
tients with MI. These findings differ from previous studies.
A total of 163 male patients (50 years old) with diagnosis of
MI have been prospectively followed (medium 72 months) in our
hospital. Clinical evolution, ACE levels, and ACE polymorphism
were studied. A control group of 100 valvular patients with normal
angiography was established (3–5). Angiographic study was done
in 41% of patients (no lesions in 9%; 49% had single-vessel disease;
29% had two-vessel disease; and 12% had three-vessel disease).
Medium-term prognosis was intermediate: three patients died,
2.5% of heart failure, 8% of reinfarction, 28% of unstable angina.
The ACE levels were higher in the DD group.
No genotype differences existed between cases and control
group (cases were: DD 44%; I/D 36%; II 20%; Control: DD 42%;
I/D 39%; II 18%). No relationship existed between ACE group
polymorphism and clinical evolution, but patients with two- and
three-vessel disease were mostly DD (p  0.01).
Thus, in this sample, we have not found a relationship between
ACE polymorphism and MI prognosis, but there seems to be a
relationship between DD and severity of coronary heart disease.
Further investigation in several aspects (both coronary heart
disease in the young and relationship with ACE polymorphism)
and long-term studies are required to clarify this controversy.
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REPLY
We read with interest the letter from Martin Fernandez et al.
regarding our study of the angiotensin-converting enzyme (ACE)
I/D polymorphism and mortality after myocardial infarction (MI).
We agree that the role of the ACE I/D polymorphism in
predicting mortality after acute MI is still controversial. However,
it is difficult to draw comparisons between our own study (1) and
that described by Martin Fernandez et al. Their study claimed to
show no relationship between ACE genotype and clinical out-
come. This is hardly surprising in a study of 163 MI patients, of
which only three died. In addition, this cohort differed greatly from
ours in being 50 years old, and all subjects were male. Our study
cohort consisted of 978 MI patients with a mean age of 62.1 years,
of which 78% were male. In addition, it is well known that
genotype frequencies differ between populations with different
ethnicities. The allele frequencies for the ACE I/D polymorphism
reported in the cases by Martin Fernandez et al. (DD 44%, I/D
36%, II 20%) are very different from most other studies of
European populations (2), including ours (DD 27.3%; I/D 49.5%;
II 23.2%). Therefore, it is difficult to draw comparisons between
such very different patient groups.
Finally, our study reported not just an association between
genotype and mortality, but it also examined the interaction
between ACE genotype and established post-infarct prognostic
markers (aminoterminal brain natriuretic peptide, N-BNP, and
left ventricular ejection fraction) to identify patients at high risk.
We believe that combining genetic data with other markers of
disease severity in this way provides superior prognostic informa-
tion.
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